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Background: Peroxisome proliferator-activated receptor g (PPARg) is a ligand-activated transcription factor, which
regulates gene expression of the key proteins involved in lipid metabolism, vascular inflammation, and proliferation.
PPARg may contribute to attenuating atherogenesis and postangioplasty restenosis. PPARg C161!T substitution is
associated with a reduced risk of coronary artery disease (CAD). Whether or not the gene substitution alters the risk
of CAD in type 2 diabetes mellitus (T2DM) patients remains unclear.
Methods: A total of 556 unrelated subjects from a Chinese Han population, including 89 healthy subjects, 78 CAD
patients, 86 T2DM patients, and 303 CAD combined with T2DM patients, were recruited to enroll in this study.
PPARgC161!T gene polymorphism was determined by polymerase chain reaction and restriction fragment length
polymorphisms. Plasma levels of lipoproteins, apolipoproteins, glucose, and insulin were measured by ELISA or
radioimmunoassay (RIA). The coronary artery lesions were evaluated by coronary angiography.
Results: The frequency of the 161T allele in CAD, T2DM, and CAD combined with T2DM patients was similar to
that observed in the healthy control group. However, in CAD combined with T2DM patients, the group with
angiographically documented moderate stenoses had a higher frequency of the 161T allele in comparison to the
group with severe stenoses (P < 0.05). Moreover, in CAD with T2DM patients, the triglyceride levels and apoB in
CC homozygote carriers were significantly higher than those in “T” allele carriers.
Conclusions: PPARgC161!T genotypes weren’t significantly associated with the risk of CAD, but were markedly
correlated with severity of disease vessels in patients with CAD and T2DM. Furthermore, PPARgC161!T
substitution was associated with an altered adipose, but not glucose metabolism. These results indicate that the
PPARg C161!T polymorphism may reduce the risk of severe atherogenesis by modulation of adipose metabolism,
especially triglycerides and apoB, in Chinese patients with CAD and T2DM.
Background
Peroxisome proliferation-act i v a t e dr e c e p t o r( P P A R )i sa
family of ligand-activated transcription factors, which
has three isotypes, namely a, b and g [1,2]. It has been
demonstrated that PPARg plays important roles in con-
trolling lipid and glucose metabolism, and is currently
known to be implicated in various metabolic diseases
such as hyperlipidemia, diabetes mellitus, and coronary
artery disease (CAD) [3,4]. Expression of PPARg has
been shown in atherosclerotic lesions and macrophage
foam cells, suggesting that PPARg may affect athero-
sclerogenic processes [5,6]. The role of PPARg in CAD
could be mediated through its effects on adipocyte dif-
ferentiation, lipid metabolism and inflammatory. The
accumulation of lipids and extracellular matrices in the
arterial intima elicits a local inflammatory response,
leading to atherosclerogenic processes [7]. PPARg ago-
nists reduce triglyceride accumulation and clinically
improve the outcome of atherosclerotic disease [8,9].
Diabetes mellitus is associated with an increased risk of
developing atherosclerotic vascular disorders and cardio-
vascular disease [10,11]. The pathogenesis of CAD in
diabetes is multifactorial in metabolic changes. The oxi-
dative stress, glycoxidation, endothelial dysfunction,
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s t a t eh a v eb e e ni m p l i c a t e dt op l a yar o l ei nt h ec a r d i o -
vascular complications of diabetes [12]. Previous studies
have shown that PPARg agonist, pioglitazone improves
endothelial dysfunction in patients with diagnosed
T2DM and CAD [13,14].
Several mutations have been reported in the PPARg
gene. Pro12Ala has been reported to be associated with
greater insulin sensitivity in childhood obesity and
increased risk for diabetes [15]. The role of another var-
iant, Pro115Gln polymorphisms, on the pathogenesis of
obesity, type 2 diabetes, and related metabolic disorders
was investigated in a Caucasian cohort, and no signifi-
cant differences were found in lipoprotein metabolism
and diabetes manifestation by comparing the different
genotypes [16]. C161!T substitution at exon 6 of the
PPARg gene has been found to be associated with insu-
lin resistance in Hispanic and non-Hispanic white
women, considers to be a better predictor of fasting
insulin levels and insulin resistance than P12A [17]. In
the Metabolic Syndrome, the CC genotype was asso-
ciated with severe lesion and the CT + TT with mild
lesion of carotid artery, which implies that PPARg
C161!T may play an important role in carotid artery
atherosclerotic [18]. However, the association between
the PPARg C161!T and the occurrence of CAD in the
Chinese Han population with or without T2DM is not
clarified.
In this study, we explored the PPARgC161!Ts u b s t i -
tution in well characterized hospital-based patients with
CAD, T2DM, or CAD with T2DM, as well as healthy
controls. The mechanism by which PPARg C161!T
alters the risk of severe vascular stenosis in the Chinese
Han population was investigated from a genetic stand-
point. Our results indicate that PPARgC161!Tm a yb e




We studied 556 kinless subjects of the Han nationality
aged 70 years or less, including men (n = 339) and
women (n = 217), consecutively admitted to the Zhong-
nan Hospital at Wuhan University and the Tongji Hos-
pital at Huazhong University of Science and Technology
from 2003 to 2007. This was the initial admission for
the diagnosis of CAD for these patients. Diagnostic cri-
teria for CAD was according to the ACC/AHA 2002
guidelines, and T2DM was according to the definition
of diabetes advocated by the American Diabetes Asso-
ciation in 1997. All underwent angiography, and each
angiogram was classified into two groups: having coron-
ary lesion coronary angiography with less than 75%
luminal stenosis or having at least one major epicardial
coronary arteries with more than 75% luminal obstruc-
tion. The diagnosis from two cardiologists, based on
coronary angiography, showed that of the 467 recruited
patients, 78 patients had CAD, 86 patients had T2DM,
and 303 patients had CAD combined with T2DM. Each
patient’s medical history was obtained using a question-
naire with standardized choices of answers to be
checked during the interview. In this study period,
patients did not use aspirin, insulin, oral hypoglycemic
agents, or any other drug that could affect the lipid pro-
file. The samples for DNA analysis were collected for
each patient as previously described [19]. This study was
approved by an external ethics committee, and written
informed consent was obtained from each patient. A
total of 89 healthy subjects were recruited in this study
as controls.
Biometric measurements
The height and weight were measured for each patient
by a registered nurse who interviewed the patients to
record the medical history. The body mass index (BMI)
was obtained from the ratio of weight (kg) to height
squared (m
2). A BMI of 20-25 was considered normal,
25-30 over-weight, and >30 obese.
Measurements of lipoproteins, apolipoproteins, blood
glucose and serum insulin
The total cholesterol (TC), HDL-cholesterol (HDL-C)
and triglyceride levels were measured in the hospital’s
Clinical Chemistry Department using standard enzy-
matic methods. The concentrations of apo A, apo B and
Lp(a) were measured using a ELISA kit following manu-
facturer’s instruction (Sigma). The LDL-cholesterol
levels were calculated using the Friedewald formula. The
concentrations of glucose and insulin were measured
during a 75-g oral glucose tolerance test, and insulin
resistance was estimated according to the homeostatic
model [20] [(homeostasis model assessment-insulin
resistance [HOMA-IR]) = fasting serum insulin × fasting
blood glucose/22.5].
Determination of the PPARg exon 6 (C161!T)
substitution
Whole blood, 5 ml samples with heparin, was collected.
DNA was extracted from blood cells using a Whole
Blood DNA Isolation Kit (Dojindo Molecular Technolo-
gies, Inc). The concentration of DNA recovered was
expressed as UV spectro photometric OD260/OD280
ratios. The polymerase chain reaction (PCR) was used
to detect the C161!Ta te x o n6o ft h eP P A R g gene as
previously described by Meirhaeghe et al [21]. The for-
ward primer was 5’-CAA GAC AAC CTG CTA CAA
GC-3’ and reverse primer was 5’-TCC TTG TAG ATC
TCC TGC AG-3’. The amplification was performed in a
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primer, 2.0 mmol/l Mgcl2,5 0m m o l / lK C l ,2 5μmol/l
dNTP and 1 Unit Taq polymerase. Samples were sub-
jected to denaturing at 94°C for 5 min followed by
35 cycles of 94°C for 1 min, 57°C for 1 min, 72°C for
1 min. The final thermal cycle was at 72 °C for 5 min.
T h e2 0 0b pP C Rp r o d u c t sw e r ed i g e s t e dw i t ha nEcoR
72I restriction enzyme and visualized by 8% agarose gel
electrophoresis.
Statistical analysis
SPSS 11.0 software was used to analyze the data. All the
continuous variables are presented as mean ± SEM. The
effects of genotypes were analysed and presented for all
three genotype groups (CC, CT and TT). Since the
number of the TT homozygous patients was small, we
combined the TT and CT into a single “T” allele carrier
group (CT+TT) to improve statistical power. We used a
one-way ANOVA and a Student t test to evaluate rela-
tionships between the PPARg genotypes and quantitative
variables. To determine the correlations between the
genotypes and other medical conditions including myo-
cardial infarction, angina pectoris, diabetes mellitus and
hypertension, a contingency table chi-square analysis
was used to analyze the contribution of the polymorph-
ism to the presence and severity of CAD. The Hardy-
Weinberg equilibrium test was performed using the
chi-square test. The statistical significance was defined
as P < 0.05.
Results
The distribution of C161!T polymorphism between
patients and the healthy controls
The length of exon 6 of PPAR gene was 249 bp, the
DNA sequence of gene nt159-164 was CACGTG which
was recognized by restriction endonucleotide enzyme
EcoR 72I. The mutation C161!T eliminates an EcoR
72I recognition site and appears a polymorphism site.
The genotypes of variants were analysed and presented
for all three genotype groups CC (CACGTG) and CT/
TT (CATGTG). In this study, polymerase chain reac-
tion-restriction fragment length polymorphism was used
to study the distribution of the PPARg C161!Tp o l y -
morphism. The primers used to amplify part of exon 6
o ft h eP P A Rg e n ew e r ed e r i v e df r o mt h eg e n o m i c
sequence of the PPAR and used of these primers gave a
PCR product of 200 bp. As shown in Figure 1, two frag-
m e n t s( 1 2 0b pa n d8 0b p )o fP C Rp r o d u c t sw e r e
observed in wild-type. Only one fragment (200 bp) was
seen in PPARgC161!T substitution, since the restric-
tion site was eliminated by the C161!T transition. The
genotypes were identified as CC, CT and TT. The most
common allele has a C at nt 161, while the variant allele
has a T at this position. The genotype distribution was
in Hardy-Weinberg equilibrium in the control group
(P = 0.97). However, no significant difference was
observed in “T” allele frequency between all patient groups
and healthy subjects. In the healthy group, “T” allele car-
ries were 21.3%, and “C” allele carries were 78.7%. How-
ever the T allele carriers in the healthy control group were
higher than those in CAD (19.8%), T2DM (20%), and
CAD combined with T2DM (19.2%) groups (Table 1).
The C161!T polymorphism and severity of
atherosclerosis and restenosis in CAD and CAD with
T2DM patients
Since the lesions (luminal obstructions) in T2DM group
patients were less than 50%, the relationship between
Figure 1 Gene type analysis of PPARg gene C161!T.M :P G E M -
7Z(+)HaeIIIDNA molecular marker
Table 1 Comparison of genotype distributions in CAD,
T2DM and CAD with T2DM
PPARg C161!T genotypes allele frequency
Groups CC CT TT C T
CAD (n = 78) 0.641(50) 0.321(25) 0.038(3) 0.802 0.198
T2DM (n = 86) 0.639(55) 0.314(27) 0.047(4) 0.796 0.20
CAD with T2DM
(n = 303)
0.650(197) 0.314 (95) 0. 036(11) 0.808 0.192
Healthy control
(n = 89)
0.618 (55) 0.337(30) 0.045(4) 0.787 0.213
No statistically significant difference was observed between the CAD patients
and healthy subjects (P >0 . 0 5 )
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and restenosis in T2MD patients was not shown in this
study. The CAD and CAD plus T2DM patients have
been divided into moderate and severe stenoses groups,
according to the severity of stenosis in the major coron-
ary arteries (modest group ≤75% but ≥ 50%, severe
group ≥ 75% luminal obstructions). In the CAD group,
simple X
2 comparison results showed that 33.1% of
the ‘T’ allele carrier had the serious vessel disease and
38.1 % of the ‘T’ allele carriers had modest vessel dis-
ease. However, there was no significant difference
between CC homozygotes and ‘T’ allele carriers (p =
0.695, Table 2). Data from the 303 CAD plus T2MD
participants are presented in Table 3. All CAD plus
T2MD patients had angiographically demonstrable cor-
onary artery disease. A total of 155 patients had severe
vessels stenosis (>75%), including 109 patients (70.3%)
with the CC genotype, and 46 patients (29.7%) with the
CT+TT genotype. A significant difference in severity of
atherosclerosis and restenosis was found between
patients with the CC genotype and patient bearing at
least one T allele (the CT/TT genotypes) in CAD plus
T2MD participants (OR = 1.22, 95%CI: 1.03-1.45, P =
0.019). This result indicates a significant association
between the 161T polymorphism and severity of dis-
eased vessels in CAD plus T2MD patients, but not in
CAD patients.
The C161!T polymorphism and lipid metabolism
In the CAD (Table 4) and T2DM (Table 5) groups, no
significant difference in lipid and blood glucose metabo-
lism, including insulin resistance, was observed between
PPARg genotypes (CC versus CT/TT). However, there
were significant differences in the levels of triglyceride
and apoB in the CAD with T2DM group between CC
genotype patients and T allele carriers (Table 6). The
differences in apoB between genotypes remained signifi-
cant after controlling for age, cigarette smoking status,
and BMI, by a general factorial model of variance
(P=0.032). Assessment-insulin resistance and blood glucose distributions showed no difference amongst all
patients in the PPARgC161!T genotype group.
Discussion
PPARg is critical transcription factor for the gene regu-
lation of glucose and lipid metabolism. Therefore
PPARg is one of the potential candidate genes for the
link between diabetes mellitus and CAD. A previous
study showed an association between C161!Tp o l y -
morphism in the PPARg gene and a reduced risk of cor-
onary artery disease in patients with and without
diabetes in an Australian Caucasian cohort [19]. How-
ever, in a German study, an association between the
C161!T polymorphism and the occurrence of coronary
heart disease in patients with diabetes mellitus was
Table 2 The correlation between PPARg polymorphism
and severity of atherosclerosis and restenosis in CAD
group (%)
PPARg genotypes
Groups CC CT TT
# CT+TT*
Modest stenosis <75% 13 (61.9%) 7 (33.3%) 1 (4.8%) 8 (38.1%)
Severe stenosis >75% 38 (66.7%) 17 (29.8%) 2 (3.5%) 19 (33.3%)
Total (78) 51 (65.4%) 24 (30.8%) 3 (3.8%) 27 (34.6%)
Number of patients is presented in each subgroup with a row percentage in
the bracket. # c
2 = 0.113, P = 0.737, for comparisons among CC, CT
genotypes. * c
2 = 0.154, P = 0.695 for comparison between CC genotype and
“T” allele carriers (CT+TT genotype).
Table 3 The correlation between PPARg polymorphism
and a severity of atherosclerosis and restenosis in CAD
with T2DM group
PPARg genotypes
Groups CC CT TT
# CT+TT*
Modest stenosis<75% 85 (57.4%) 58 (39.2%) 5(3.4%) 63(42.6%)
Severe stenosis>75% 109(70.3%) 39(25.2%) 7(4.5%) 46(29.7%)
Total (303) 194(64%) 97(32%) 12(4%) 109(36%)
Number of patients is presented in each subgroup with a row percentage in
the bracket. #c
2 = 6.607, P = 0.010, for comparisons among CC, CT and TT
genotypes. *c
2 = 5.462, P = 0.019 for comparison between CC genotype and
“T” allele carriers (CT+TT genotype). Taking CC genotype as the risk allele, the
corresponding odds ratio with 95% confidential interval is 1.22 (1.03-1.45).
Table 4 Biometric, lipoprotein profile distributions,
assessment-insulin resistance and blood glucose











Age 62.40 ± 12.04 67.75 ± 11.18 63.00 ± 8.73 66.80 ± 10.12
Weight (kg) 62.93 ± 9.59 58.23 ± 7.13 58.67 ± 7.51 58.32 ± 6.9 2
Height (m) 1.61 ± 0.07 1.63 ± 0.09 1.61 ± 0.06 1.63 ± 0.08
BMI (kg/m
2) 22.48 ± 6.60 21.79 ± 3.14 23.01 ± 3.14 22.05 ± 3.06
TC (mmol/L) 4.37 ± 1.32 4.76 ± 1.36 3.82 ± 0.88 4.57 ± 1.31
Trig (mmol/L) 1.65 ± 0.89 1.51 ± 0.85 1.70 ± 0.82 1.55 ± 0.82
HDL (mmol/L) 1.21 ± 0.23 1.58 ± 0.62 1.13 ± 0.18 1.49 ± 0.59
LDL (mmol/L) 2.82 ± 0.69 2.77 ± 1.05 2.09 ± 0.60 2.63 ± 0.99
apoA1 (g/L) 1.29 ± 0.17 1.39 ± 0.22 1.27 ± 0.08 1.37 ± 0.20
apoB (g/L) 1.08 ± 0.11 0.87 ± 0.29 0.74 ± 0.28 0.85 ± 0.29
Lp(a) (mg/L)
Δ 1.90 ± 0.64 1.89 ± 0.58 1.25 ± 0.03 1.78 ± 0.58
FBS (mmol/L) 5.49 ± 0.77 5.78 ± 0.75 5.46 ± 1.06 5.71 ± 0.79
PPBS (mmol/L) 6.38 ± 1.22 8.17 ± 2.03 6.87 ± 0.28 7.87 ± 1.85
RI
Δ 1.08 ± 0.16 1.03 ± 0.21 1.12 ± 0.14 1.05 ± 0.19
No statistically significant difference was observed between the gene type
groups (P > 0.05)
Δ The measurement material were descriptive statistics of skewed distribution,
and counted after logarithm
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gene C161!T substitution was associated with reduced
risk of coronary artery disease through modulation of
pro-inflammatory cytokines, MMP-9 and TNF-a expres-
sion in a Chinese population [23]. Therefore, it has not
clear if PPARg gene C161!T substitution is associated
with CAD in patients with or without T2MD. In this
study, we investigated the correlation between the
PPARg C161!T and the occurrence of CAD in a Chi-
nese Han population with or without T2DM, in order
to determine a possible genetic marker to predict the
development of CAD in patients with diabetes. We
could not demonstrate a significant association of the
PPARg-C 1 6 1 !T genotype with CAD in the Chinese
Han population with or without T2DM. However,
PPARg-C 1 6 1 !T markedly correlated with severity of
atherosclerosis in patients with CAD with T2DM, which
is through a mechanism underlying an altered lipid, but
not glucose, metabolism.
Patients with diabetes mellitus have an increased risk
of premature atherosclerosis [24]. T2DM causes more
than two-fold increased incidence of myocardial infarc-
tion and CAD related death. Moreover, T2DM, but not
coronary atherosclerosis was found to be an indepen-
dent determinant of impaired mobility in the high risk
population of patients with CAD who underwent angio-
graphy [25]. These data support the concept that dia-
betes is a major independent risk factor for CHD [26].
Both of CAD and T2DM have insulin resistance and
hyperlipidemia, which produces detrimental effects on
vasculature. High plasma glucose is known to be asso-
ciated with the severity of coronary artery disease
[27,28]. In this study, we evaluated the relationship
between the PPARg mutation and insulin resistance.
Consistent with a previous report that studied a Brazi-
lian population [29], we found that PPARgC161!Tw a s
not associated with insulin sensitivity and blood glucose
level. However, a significant reduction of serum trigly-
cerides was observed in the “T” allele carriers in patients
with CAD and T2DM. Higher levels of apoB strongly
correlated with elevated blood glucose levels and
resulted in the occurrence of CAD. Moreover, high
levels of apoB caused more inflammation and thrombo-
sis in comparison with high levels of LDL. In this study,
we also found that the level of apoB was higher in the
CC genotype than the “T” allele carriers (CT+TT) in
CAD combined with T2DM patients, indicating that
PPARgC161!T reduces the risk of hyperlipidemia, and
further diminishes the risk of severity of atherosclerotic
vessels in patients with CAD and T2DM. Although
CAD and T2DM are strongly associated with disorders
of lipid metabolism, in our study, no significant differ-
ences in the levels of triglyceride and apoB were seen
between the “C” and “T” allele carriers in the patients
with CAD or T2DM, but a significant difference was
observed in the patients with CAD and T2DM. This
Table 5 Biometric, lipoprotein profile distributions,
assessment-insulin resistance and blood glucose











Age 58.13 ± 10.68 54.80 ± 11.05 56.50 ± 13.40 55.26 ± 12.21
Weight (kg) 66.10 ± 12.15 62.30 ± 9.06 69.38 ± 12.93 63.79 ± 10.02
Height (m) 1.65 ± 0.09 1.63 ± 0.07 1.66 ± 0.09 1.64 ± 0.07
BMI (kg/m
2) 24.69 ± 4.65 23.04 ± 3.36 25.08 ± 4.67 23.62 ± 3.71
TC (mmol/L) 4.56 ± 0.89 4.42 ± 0.73 4.13 ± 0.34 4.36 ± 0.67
Trig (mmol/L) 1.93 ± 1.74 1.68 ± 1.02 1.77 ± 0.38 1.70 ± 0.92
HDL(mmol/L) 1.10 ± 0.37 1.27 ± 0.42 1.14 ± 0.27 1.25 ± 0.39
LDL (mmol/L) 2.77 ± 0.76 2.56 ± 0.70 2.49 ± 0.41 2.55 ± 0.64
apoA (g/L) 1.27 ± 0.19 1.39 ± 0.24 1.31 ± 0.13 1.36 ± 0.20
apoB (g/L) 1.14 ± 0.36 0.98 ± 0.16 1.03 ± 0.20 0.99 ± 0.18
Lp(a) (mg/L)
Δ 1.66 ± 0.64 1.67 ± 0.46 1.24 ± 0.04 1.53 ± 0.43
FBS (mmol/L) 9.58 ± 1.80 9.92 ± 2.35 10.31 ± 0.93 10.01 ± 2.11
PPBS (mmol/L) 13.38 ± 3.43 14.05 ± 4.22 15.07 ± 2.73 14.26 ± 3.
RI
Δ 1.84 ± 0.27 1.87 ± 0.25 1.77 ± 0.27 1.85 ± 0.25
No statistically significant difference was observed between the gene type
groups (P>0.05)
Δ The measurement material were descriptive statistics of skewed distribution,
and counted after logarithm
Table 6 Biometric, lipoprotein profile distributions,
assessment- insulin resistance and blood glucose
distributions in relation to the PPARg C161!T genotypes










Age 62.64 ± 11.22 63.00 ± 12.87 66.00 ± 11.33 63.49 ± 12.61
Weight (kg) 64.35 ± 11.09* 60.82 ± 9.16* 61.21 ± 7.31 61.38 ± 9.24
Height (m) 1.64 ± 0.09 1.63 ± 0.07 1.64 ± 0.07 1.63 ± 0.07
BMI (kg/m
2) 23.94 ± 5.50 22.57 ± 3.62 24.06 ± 3.22 22.82 ± 3.58
TC (mmol/L) 4.66 ± 1.09 4.54 ± 1.17 4.19 ± 0.68 4.48 ± 1.11
Trig (mmol/L) 2.52 ± 1.59 * 1.68 ± 0.96 * 1.64 ± 0.46 1.67 ± 0.89*
HDL (mmol/L) 1.21 ± 0.38 1.22 ± 0.43 1.22 ± 0.24 1.22 ± 0.41
LDL (mmol/L) 2.74 ± 0.73 2.73 ± 0.91 2.38 ± 0.86 2.68 ± 0.90
apoA1 (g/L) 1.27 ± 0.19 1.25 ± 0.24 1.26 ± 0.10 1.25 ± 0.22
apoB (g/L) 1.02 ± 0.22* 0.94 ± 0.24* 0.94 ± 0.19 0.94 ± 0.23*
Lp(a) (mg/L)
Δ 1.82 ± 0.52 1.82 ± 0.53 1.32 ± 0.22 1.75 ± 0.53
FBS (mmol/L) 6.80 ± 2.26 7.32 ± 2.81 7.24 ± 2.49 7.23 ± 2.74
PPBS (mmol/L) 9.58 ± 3.90 10.73 ± 4.83 10.37 ± 4.36 10.67 ± 4.73
RI
Δ 1.42 ± 0.38 1.48 ± 0.42 1.34 ± 0.37 1.45 ± 0.41
* p < 0.05. P values were obtained by ANOVA F tests for comparisons among
CC, CT and TT genotypes or Student t test for comparisons between CC
genotype and T allele carriers (CT+TT genotypes).
Δ The measurement material were descriptive statistics of skewed distribution,
and counted after logarithm
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lism is increased when patients are classified as CAD
plus T2DM. PPARg C161!T may reduce this risk.
Furthermore, severity of atherosclerosis and re-stenosis
in CAD patients was not associated with genotypes, but
“C” carriers in comparison with “T” carriers had a
higher risk of severe atherosclerosis and re-stenosis in
the patients with CAD and T2DM. This result further
suggests that disorders of lipid metabolism may result in
severe CAD. 70.5% patients with CAD and T2DM
whose vascular stenosis was more than 75% had the CC
gene type, thereby suggesting that diabetes can increase
the severity of CAD.
In summary, we have found that the PPARgC161!T
was associated with a reduced risk of severity of stenosis
and lipid metabolism disorder in Chinese patients with
CAD and T2DM. PPARgC161!T has a significant pro-
tective effect on atherogenesis in CAD and T2DM
patients by modulating lipid metabolism. “T” allele car-
riers may transmit their genetic characteristics in the
Han population to reduce the risk of severity of stenosis
in patients with CAD and T2DM.
Conclusion
PPARgC161!T genotypes weren’t significantly asso-
ciated with the risk of CAD, but were markedly corre-
lated with severity of disease vessels in patients with
C A Da n dT 2 D M .F u r t h e r m o r e ,P P A R gC161!Ts u b s t i -
tution was associated with an altered adipose, but not
glucose metabolism. These results indicate that the
PPARg C161!T polymorphism may reduce the risk of
severe atherogenesis by modulation of adipose metabo-
lism, especially triglycerides and apoB, in Chinese
patients with CAD and T2DM.
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